United States: FDA's Proposal For Naming Biosimilars Pleases Some, Disappoints Others

Last Updated: September 22 2015
Article by Elizabeth L. Callahan and Irena Royzman

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar biological products, but is silent on how to name them. The nonproprietary naming of biosimilars has been an area of controversy because, unlike generic drugs, biosimilar biological products are only biosimilar to and cannot be the same as the originator product. Many have argued that distinct nonproprietary names (also known as proper names) for originator products and their biosimilars are necessary to protect patients. Biosimilar makers have argued that distinct names will impede the adoption of biosimilars.

After years of debate, FDA released a draft guidance that adopts a middle-road approach. Unlike small-molecule drugs, where the branded and generic drugs share the same nonproprietary name, FDA's guidance provides distinct nonproprietary names for biological products. FDA proposes that all biological products carry the nonproprietary name of the originator biological product, along with a unique suffix to identify originator biological products, related biological products, and biosimilar products. But FDA's proposed unique suffix is a random collection of four letters that is neither meaningful nor memorable. It is "devoid of meaning" to address concerns of biosimilar makers that distinctive names will discourage adoption of biosimilars.

The FDA's guidance document has been long-awaited by the healthcare industry. Under the new guidance, healthcare providers will be able to differentiate among biological products to minimize inadvertent substitution of biological products that have not been determined by the FDA to be interchangeable. According to the FDA, the new naming convention is designed to "maximize the success of biosimilar products and interchangeable products and to help ensure the safety of patients receiving biological products licensed under the [Public Health Services] Act."

In practice, the FDA intends to use a "core name" that is shared among all related biological products. For originator biological products, FDA will use the name adopted by the USAN Council for the drug substance as the core name. If the biological product is a related, biosimilar, or interchangeable product, the core name will be the nonproprietary name of the originator biological product, e.g., filgrastim in the case of Amgen's Neupogen. A suffix of four lowercase letters will be added to the core name of each biological product, including the originator product, with a hyphen. The suffix must be a unique series of four letters and may not be promotional, such as making misrepresentations with respect to safety or efficacy. For example, Sandoz's Zarxio, a biosimilar of Amgen's Neupogen product, will have the nonproprietary name "filgrastim-bflm." Zarxio had previously been given the placeholder name "filgrastim-sndz."

According to the FDA, the suffix "will provide a consistent, readily available and recognizable mechanism for patients and health care professionals, including providers and pharmacists, to correctly identify these products." FDA chose a suffix instead of a prefix so that products with the same core name will be grouped together in electronic databases.

The FDA explained that by requiring suffixes for all biological products, including originator products, it intends to promote pharmacovigilance while "avoid[ing] inaccurate perceptions of the safety and effectiveness of biological products based on their licensure pathway." That is, requiring both originator and biosimilar biological products to carry a four-letter suffix will avoid giving medical professionals and patients the impression that biosimilar products differ from the originator products in a clinically meaningful way. The FDA does, however, request feedback from the public as to whether the nonproprietary name for an interchangeable biological product should share the same suffix as the originator product. Comments should be submitted by October 27, 2015.

The FDA is also seeking comment on the best approach to implementing its naming convention for previously licensed products. It has issued a proposed rule to designate nonproprietary names with distinguishing suffixes for six previously licensed biological products. Each of the six products is either an originator biologic for an approved or publicly disclosed biosimilar application or a biological product that is related to one of the originator biologics. The proposed nonproprietary name for Amgen's Neupogen, for example, is "filgrastim-jcwp." Comments on the rule should be submitted by November 12, 2015.

Patient advocacy groups praised FDA's guidance, saying that distinctive names are needed for patient safety. The American College of Rheumatology said that "[d]istinctive names will allow for greater transparency in substitution and notification, making it clear to all parties involved – pharmacists, providers and patients – which drug the patient is receiving." The Global Healthy Living Foundation called FDA's guidance "a major win for patients and physicians." The Biologics Prescribers Collaborative (BPC) also commended FDA's decision to require distinctive names. BPC said that the "prescribers who work every day with biologics – and their patients – are winners from FDA's decision. The agency recognized that distinguishable names are essential to pharmacovigilance, patient safety, and transparency."

The Alliance for Safe Biologic Medicines (ASBM), a group of biotech companies, was supportive of FDA's decision to use distinctive names but thought the guidance did not go far enough. The ASBM called for a "meaningful, intuitive suffix applied consistently to all products by a single manufacturer" as opposed to FDA's proposal for a suffix "devoid of meaning." ASBM pointed to FDA's placeholder name for Sandoz' Zarxio as "filgrastim-sndz" as an example of a nonproprietary name with a meaningful suffix, explaining that the "sndz" suffix was "not only memorable and logical" but also promoted manufacturer accountability by associating the product with its manufacturer. FDA is soliciting public feedback on precisely this issue, i.e., "the benefits and challenges of [using] ... a suffix derived from the name of the license holder."

By contrast, the Biosimilars Council, a division of the Generic Pharmaceutical Association was disappointed with any distinctive names. It argued that FDA's "naming conventions warrant serious scrutiny for their potential to erect barriers to patient access to new, more affordable medicines, and jeopardizes their safety." The Biosimilars Counsel said that "[a]dding a random collection of letters to the product's nonproprietary name confers no additional safety benefit, and in fact would require the healthcare professional to be armed at all times with a code-breaking reference." The Academy of Managed Care Pharmacy (AMCP) also voiced its disappointment with FDA's decision to use distinctive nonproprietary names. AMCP expressed "concern[] that any departure from the currently accepted nonproprietary naming system will create confusion amongst healthcare practitioners and patients, have negative effects on the ability to ensure safe dispensing and tracking, and result in lower market adoption and cost-savings."

The FDA's draft guidance and proposed rule will undoubtedly receive significant public comment before they are finalized. In the meanwhile, patients and healthcare providers are satisfied with FDA's middle-road approach.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions